Business Context and Reporting Period
This Form 8-K Current Report was filed by Nile Therapeutics, Inc. (not Capricor Therapeutics, Inc.) on February 26, 2008, covering events occurring on February 22, 2008. The filing reports the appointment of a new senior executive officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to executive compensation:
- Annual Base Salary: $250,000
- Signing Bonus: $42,000 (one-time)
- Discretionary Bonus: Up to 30% of annual base salary
- Stock Options: 200,000 shares (standard), up to 100,000 shares (performance-based), and 125,000 shares (technology acquisition-related)
Material Changes
The material change reported is the appointment of Hsiao Dee Lieu, M.D., F.A.C.C. as Vice President of Clinical Research. Dr. Lieu brings significant experience in translational research and clinical execution of Phase III trials, having previously served as Director of Clinical Development for Portola Pharmaceuticals, Inc. and Director of Clinical Research and Development at CV Therapeutics, Inc.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The appointment is intended to leverage Dr. Lieu's expertise in molecular cardiology and clinical trial execution. The stock options granted are subject to Board approval and vesting schedules detailed in the attached Offer Letter.
Investor Verification Checklist
- Verify the correct registrant name is Nile Therapeutics, Inc., not Capricor Therapeutics, Inc.
- Confirm the vesting schedules and performance milestones for the 425,000 total shares of stock options granted.
- Review the attached Offer Letter (Exhibit 10.1) for specific terms regarding the discretionary bonus and termination provisions.
- Check subsequent filings for the Board of Directors' formal approval of the stock option grants.